I suspect the market wants to see some consistency, i.e. can RHT win another large contract before the current pharma clinical trial runs out? Can the pipeline convert?
No guarantee that revenue won't slip back to circa $1m a quarter once the current ~18month contracted clinical trial (announced Aug 2023) wraps up in the 1st half of 2025 calendar year.
So, perhaps if one or two more runs (hopefully of a similar size to the $6m valued trial contract) come on board this year the confidence improves and demand grows.
RHT Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
